We are excited to announce that we will attend the 28th Annual ASGCT Meeting! Join us from May 13–17, 2025, in New Orleans for the American Society of Gene and Cell Therapy’s (ASGCT) Annual Meeting, the premier event for gene and cell therapy professionals. This conference brings together research, industry, and regulatory experts to explore the latest advancements, technologies, and innovations. Don’t miss this opportunity to engage with leaders, discover cutting-edge research, and expand your professional network. See you in New Orleans!
What is the ASGCT Annual Meeting?
The 28th Annual ASGCT Meeting will occur in New Orleans from May 13th to the 17th, bringing together leading gene and cell therapy experts. This premier event features keynote-level talks, cutting-edge research presentations, and networking opportunities, continuing ASGCT's tradition of milestone agendas that shape the future of the field. ASGCT is an opportunity to engage with top scientists, clinicians, and industry professionals at the year's most comprehensive gene and cell therapy conference!
Event Overview
Date: May 13-17, 2025
Venue: The New Orleans Ernest N. Morial Convention Center, 900 Convention Center Blvd, New Orleans, LA
Event Schedule
The 2025 ASGCT Annual Meeting will include a variety of workshops, general sessions, and scientific symposiums scheduled across different days, times, and in multiple locations. Feel free to find the sessions that interest you most in the official schedule. Refer to ASGCT 2025 for the full program and details.
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We look forward to seeing you at the 28th ASGCT Annual Meeting in New Orleans, LA!
